Maintenance Intermittent Therapy for Symptomatic GERD Patients
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a
maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal
Reflux Disease (s-GERD).